Author/Authors :
Cortegiani Andrea نويسنده Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia Analgesia Intensive Care and Emergency, Pocliclinico P. Giaccone University of Palermo, Italy , Russotto Vincenzo نويسنده Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia Analgesia Intensive Care and Emergency, Pocliclinico P. Giaccone University of Palermo, Italy , Iozzo Pasquale نويسنده General Intensive Care Unit, Policlinico P. Giaccone. University of Palermo, Italy , Raineri Santi Maurio نويسنده Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia Analgesia Intensive Care and Emergency, Pocliclinico P. Giaccone University of Palermo, Italy , Giarratano Antonino نويسنده Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia Analgesia Intensive Care and Emergency, Pocliclinico P. Giaccone University of Palermo, Italy
Abstract :
Invasive fungal infections (IFIs) are associated with high morbidity and mortality in intensive care units. Candida species are the most important fungal pathogens and among the most frequent causes of infection in critically ill patients. Studies have evaluated the correlation between the onset of antifungal treatment and survival. However, definitive diagnosis of IFI is time-consuming in clinical practice. Antifungal prophylaxis and preemptive or empirical treatments are among therapeutic strategies to prevent or treat early fungal infections in selected patients. Recently, new evidence from randomized controlled trials and systematic reviews has been published. Moreover, new clinical practice guidelines from international communities are available. The aim of this review was to present updated evidence on this topic.
